Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).
On February 21, 2026, Abivax presented new preclinical and clinical data on its lead candidate obefazimod at the European Crohn’s and Colitis Organization’s 21st Annual Congress, highlighting the first evidence of anti-fibrotic activity in human fibroblast and animal models relevant to Crohn’s disease. The company also reported pooled Phase 3 ABTECT induction data in ulcerative colitis showing a favorable safety profile comparable to placebo, rapid symptomatic improvement from week 1 with remission by week 2, and biomarker results consistent with its miR-124–mediated mechanism, reinforcing obefazimod’s potential as a differentiated oral therapy in inflammatory bowel disease.
In a safety analysis of 1,272 patients, serious treatment-emergent adverse events and discontinuations were similar between obefazimod and placebo, while headaches were generally mild and transient. Biomarker findings showed increased miR-124 expression and reductions in key inflammatory cytokines IL-17A and IL-6 toward homeostatic levels, and external clinical experts noted that the combination of anti-fibrotic signals, symptom relief, and safety could mark a meaningful advance for patients if these results continue to translate in ongoing Phase 3 and Phase 2b programs.
The most recent analyst rating on (ABVX) stock is a Buy with a $142.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The score is primarily held down by weak financial performance—ongoing losses, negative operating cash flow, and reliance on financing with high leverage. Technicals offer only moderate support with a longer-term uptrend but weaker near-term momentum, while valuation lacks support due to negative earnings and no dividend yield.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in France and the United States, developing therapies that harness the body’s natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead product candidate, obefazimod (ABX464), is in Phase 3 trials for moderately to severely active ulcerative colitis, targeting the inflammatory bowel disease market.
Average Trading Volume: 1,536,103
Technical Sentiment Signal: Buy
Current Market Cap: $10.26B
See more data about ABVX stock on TipRanks’ Stock Analysis page.